drugset / Trial / NCT05650203
A Study of JS009 Monotherapy and JS009 as a Triple Combination Therapy in Patients With Advanced Malignancies
NaSingle-groupOpen-labelTreatment
Summary
The study is being conducted to evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy JS009 as a monotherapy and JS009 as a Triple Combination Therapy in Combination with Toripalimab and JS006 in Patients with Advanced Malignancies, also to explore the RP2D of JS009.
Timeline
- Start
- 2023-03-31
- Primary completion
- 2025-10-25
- Completion
- 2026-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | JS009 | Unknown | 18 mg | Intravenous |
| Subject | JS009 | Unknown | 60 mg | Intravenous |
| Subject | JS009 | Unknown | 180 mg | Intravenous |
| Subject | JS009 | Unknown | 600 mg | Intravenous |
| Subject | JS009 | Unknown | 1200 mg | Intravenous |
| Background | JS006 | Monoclonal antibody | 600 mg | Intravenous |
| Background | Toripalimab | Monoclonal antibody | 240 mg | Intravenous |